Abstract: In order to explore a safer sugar control method without side effects, a strain of Lactobacillus brevis SLB1000screened in the laboratory was tested in vivo to observe its possible probiotic effects, so as to provide a basis for the research and utilization of probiotics. SD rats were used to construct type Ⅱ diabetes model rats. Different doses of SLB1000(1×10~8CFU/mL, 1×10¹⁰CFU/mL)were gavaged, and the body weight, fasting blood glucose and oral glucose tolerance（OGTT） of rats were measured regularly. On the 75th day of the experiment, the rats were dissected, the organ index, the activity of antioxidant enzymes in serum and liver of rats were measured. The results showed that Lactobacillus brevis SLB1000 delayed the type Ⅱ diabetes-induced weight loss of rats, and reduced fasting blood glucose in a dose-dependent manner. Compared with the model group, the high-dose group(1×10¹⁰CFU/mL) could inhibit weight loss by 12.82%, reduce fasting blood glucose by 67.21%, reach to 6.43 mmol/L, and reduce kidney and liver indices by 20.95% and 27.62%, respectively, which was better than metformin and effectively alleviated organ hypertrophy.Lactobacillus brevis SLB1000 could also increase the activities of superoxide dismutase（SOD）, glutathione peroxidase（GSH-Px） and catalase（CAT） in the body, effectively reduce the blood sugar level of type Ⅱ diabetes rats, significantly improve glucose tolerance and antioxidant capacity. Which suggests that the strain has good development potential.